drugset / Trial / NCT02675452
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The main objectives are to evaluate the safety and tolerability of AMG 176 monotherapy in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia.
Timeline
- Start
- 2016-06-13
- Primary completion
- 2024-05-27
- Completion
- 2024-05-27
Outcome
Outcome not reported
Stopped (Business): “sponsor decision, unrelated to safety”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TAPOTOCLAX | Small molecule | — | Intravenous |
| Background | Azacitidine | Other / unclassified | — | — |
| Background | Itraconazole | Small molecule | — | — |